.png)
Anti-Obesity Therapeutics Market by Product Type and Application - Global Industry Analysis & Forecast to 2027
Published On : September 2019 Pages : 157 Category: Pharma & Healthcare Report Code : HC095505
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Anti-Obesity Therapeutics Market by Product Type (Centrally Acting Anti-obesity Drugs, Peripherally Acting Anti-obesity Drugs) Application (Hospital Use, Clinic Use, Other) - Global Industry Analysis & Forecast to 2027
Industry Outlook and Trend Analysis
The anti-obesity therapeutics market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period. Obesity is a state of being exceptionally fat and overweight. Anti-obesity therapeutics are alluded as the treatment that decreases and control the body weight. The obesity is ascending because of the absence of physical exercises, inappropriate or absence of rest, unhealthy eating regimen, and inexpensive food and heredity history of the individual. The ideal anti-obesity therapeutics follows mechanisms that manage vitality balance which have considerable worked in-repetition and cover with other physiological elements of the body.
Drivers and Restraints
Increasing prevalence of obesity drives the growth of anti-obesity therapeutics market. Changing lifestyle of people, absence of physical exercises, increasing health concerns propels the growth of anti-obesity therapeutics market. Rise in consumption of fast food fuels the growth of anti-obesity therapeutics market. Rising expenditure on healthcare boosts the growth of anti-obesity therapeutics market. Research and development activities in order to enhance the anti-obesity therapeutic effectiveness contribute to the growth of anti-obesity therapeutics market. Some side effects of anti-obesity therapeutics may hamper the growth of anti-obesity therapeutics market.
Regional Insights
Among the geographies, North America is expected to dominate the anti-obesity therapeutics market. Rising expenditure on healthcare in the region contribute to the growth of anti-obesity therapeutics market.
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Southeast Asia
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Columbia
- Rest of South America
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Nigeria
- South Africa
- Rest of MEA
Competitive Analysis
The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
- Bristol-Myers Squibb
- Norgine Pharmaceuticals Ltd
- Eisai Company
- Vivus, Zafgen
- Takeda Pharmaceutical
- FlaxoSithKline plc
- Rhythm Pharmaceuticals
- Pfizer
- Novo Nordisk
- Shionogi USA
Some of the key questions answered by the report are:
- What was the market size in 2017 and forecast from 2017 to 2027?
- What will be the industry market growth from 2017 to 2027?
- What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
- What are the major segments leading the market growth and why?
- Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
· Anti-Obesity Therapeutics Market, By Product Type, Estimates and Forecast, 2017-2027 ($Million)
o Centrally Acting Anti-obesity Drugs
o Peripherally Acting Anti-obesity Drugs
· Anti-Obesity Therapeutics Market, By Application, Estimates and Forecast, 2017-2027 ($Million)
o Hospital Use
o Clinic Use
o Other
· Anti-Obesity Therapeutics Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)
o Bristol-Myers Squibb
o Norgine Pharmaceuticals Ltd
o Eisai Company
o Vivus, Zafgen
o Takeda Pharmaceutical
o FlaxoSithKline plc
o Rhythm Pharmaceuticals
o Pfizer
o Novo Nordisk
o Shionogi USA
· Anti-Obesity Therapeutics Market, By Region, Estimates and Forecast, 2017-2027 ($Million)
o North America
§ North America Anti-Obesity Therapeutics Market, By Country
o U.S. Anti-Obesity Therapeutics Market
o Canada Anti-Obesity Therapeutics Market
o Mexico Anti-Obesity Therapeutics Market
o Europe
§ Europe Anti-Obesity Therapeutics Market, By Country
· Germany Anti-Obesity Therapeutics Market
o UK Anti-Obesity Therapeutics Market
o France Anti-Obesity Therapeutics Market
o Russia Anti-Obesity Therapeutics Market
o Italy Anti-Obesity Therapeutics Market
o Rest of Europe Anti-Obesity Therapeutics Market
o Asia-Pacific
§ Asia-Pacific Anti-Obesity Therapeutics Market, By Country
o China Anti-Obesity Therapeutics Market
o Japan Anti-Obesity Therapeutics Market
o South Korea Anti-Obesity Therapeutics Market
o India Anti-Obesity Therapeutics Market
o Southeast Asia Anti-Obesity Therapeutics Market
o Rest of Asia-Pacific Anti-Obesity Therapeutics Market
o South America
§ South America Anti-Obesity Therapeutics Market
o Brazil Anti-Obesity Therapeutics Market
o Argentina Anti-Obesity Therapeutics Market
o Columbia Anti-Obesity Therapeutics Market
o Rest of South America Anti-Obesity Therapeutics Market
o Middle East and Africa
§ Middle East and Africa Anti-Obesity Therapeutics Market
o Saudi Arabia Anti-Obesity Therapeutics Market
o UAE Anti-Obesity Therapeutics Market
o Egypt Anti-Obesity Therapeutics Market
o Nigeria Anti-Obesity Therapeutics Market
o South Africa Anti-Obesity Therapeutics Market
o Rest of MEA Anti-Obesity Therapeutics Market
Table of Contents:
1. Introduction
1.1. Report Description
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Market Analysis by Regions
4.1. North America (United States, Canada and Mexico)
4.1.1. United States Market Status and Outlook (2017-2027)
4.1.2. Canada Market Status and Outlook (2017-2027)
4.1.3. Mexico Market Status and Outlook (2017-2027)
4.2. Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
4.2.1. Germany Market Status and Outlook (2017-2027)
4.2.2. France Market Status and Outlook (2017-2027)
4.2.3. UK Market Status and Outlook (2017-2027)
4.2.4. Russia Market Status and Outlook (2017-2027)
4.2.5. Italy Market Status and Outlook (2017-2027)
4.2.6. Rest of Europe Market Status and Outlook (2017-2027)
4.3. Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)
4.3.1. China Market Status and Outlook (2017-2027)
4.3.2. Japan Market Status and Outlook (2017-2027)
4.3.3. Korea Market Status and Outlook (2017-2027)
4.3.4. India Market Status and Outlook (2017-2027)
4.3.5. Southeast Asia Market Status and Outlook (2017-2027)
4.3.6. Rest of Asia-Pacific Market Status and Outlook (2017-2027)
4.4. South America (Brazil, Argentina, Columbia and Rest of South America)
4.4.1. Brazil Market Status and Outlook (2017-2027)
4.4.2. Argentina Market Status and Outlook (2017-2027)
4.4.3. Columbia Market Status and Outlook (2017-2027)
4.4.4. Rest of South America Market Status and Outlook (2017-2027)
4.5. Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)
4.5.1. Saudi Arabia Market Status and Outlook (2017-2027)
4.5.2. United Arab Emirates Market Status and Outlook (2017-2027)
4.5.3. Egypt Market Status and Outlook (2017-2027)
4.5.4. Nigeria Market Status and Outlook (2017-2027)
4.5.5. South Africa Market Status and Outlook (2017-2027)
4.5.6. Turkey Market Status and Outlook (2017-2027)
4.5.7. Rest of Middle East and Africa Market Status and Outlook (2017-2027)
5. Anti-Obesity Therapeutics Market, By Product Type
5.1. Introduction
5.2. Global Anti-Obesity Therapeutics Revenue and Market Share by Product Type (2017-2027)
5.2.1. Global Anti-Obesity Therapeutics Revenue and Revenue Share by Product Type (2017-2027)
5.3. Centrally Acting Anti-obesity Drugs
5.3.1. Global Centrally Acting Anti-obesity Drugs Revenue and Growth Rate (2017-2027)
5.4. Peripherally Acting Anti-obesity Drugs
5.4.1. Global Peripherally Acting Anti-obesity Drugs Revenue and Growth Rate (2017-2027)
6. Anti-Obesity Therapeutics Market, By Application
6.1. Introduction
6.2. Global Anti-Obesity Therapeutics Revenue and Market Share by Application (2017-2027)
6.2.1. Global Anti-Obesity Therapeutics Revenue and Revenue Share by Application (2017-2027)
6.3. Hospital Use
6.3.1. Global Hospital Use Revenue and Growth Rate (2017-2027)
6.4. Clinic Use
6.4.1. Global Clinic Use Revenue and Growth Rate (2017-2027)
6.5. Other
6.5.1. Global Other Revenue and Growth Rate (2017-2027)
7. Anti-Obesity Therapeutics Market, By Region
7.1. Introduction
7.2. Global Anti-Obesity Therapeutics Revenue and Market Share by Regions
7.2.1. Global Anti-Obesity Therapeutics Revenue by Regions (2017-2027)
7.3. North America Anti-Obesity Therapeutics by Countries
7.3.1. North America Anti-Obesity Therapeutics Revenue and Growth Rate (2017-2027)
7.3.2. North America Anti-Obesity Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.3.3. United States
7.3.3.1. United States Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.4. Canada
7.3.4.1. Canada Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.3.5. Mexico
7.3.5.1. Mexico Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4. Europe Anti-Obesity Therapeutics by Countries
7.4.1. Europe Anti-Obesity Therapeutics Revenue and Growth Rate (2017-2027)
7.4.2. Europe Anti-Obesity Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.4.3. Germany
7.4.3.1. Germany Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.4. France
7.4.4.1. France Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.5. UK
7.4.5.1. UK Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.6. Russia
7.4.6.1. Russia Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.7. Italy
7.4.7.1. Italy Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.4.8. Rest of Europe
7.4.8.1. Rest of Europe Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5. Asia-Pacific Anti-Obesity Therapeutics by Countries
7.5.1. Asia-Pacific Anti-Obesity Therapeutics Revenue and Growth Rate (2017-2027)
7.5.2. Asia-Pacific Anti-Obesity Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.5.3. China
7.5.3.1. China Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.4. Japan
7.5.4.1. Japan Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.5. Korea
7.5.5.1. Korea Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.6. India
7.5.6.1. India Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.7. Southeast Asia
7.5.7.1. Southeast Asia Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.5.8. Rest of Asia-Pacific
7.5.8.1. Rest of Asia-Pacific Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6. South America Anti-Obesity Therapeutics by Countries
7.6.1. South America Anti-Obesity Therapeutics Revenue and Growth Rate (2017-2027)
7.6.2. South America Anti-Obesity Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.6.3. Brazil
7.6.3.1. Brazil Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.4. Argentina
7.6.4.1. Argentina Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.5. Columbia
7.6.5.1. Columbia Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.6.6. Rest of South America
7.6.6.1. Rest of South America Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7. Middle East and Africa Anti-Obesity Therapeutics by Countries
7.7.1. Middle East and Africa Anti-Obesity Therapeutics Revenue and Growth Rate (2017-2027)
7.7.2. Middle East and Africa Anti-Obesity Therapeutics Revenue (Million USD) by Countries (2017-2027)
7.7.3. Saudi Arabia
7.7.3.1. Saudi Arabia Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.4. United Arab Emirates
7.7.4.1. United Arab Emirates Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.5. Egypt
7.7.5.1. Egypt Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.6. Nigeria
7.7.6.1. Nigeria Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.7. South Africa
7.7.7.1. South Africa Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.8. Turkey
7.7.8.1. Turkey Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
7.7.9. Rest of Middle East and Africa
7.7.9.1. Rest of Middle East and Africa Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
8. Company Profiles
8.1. Bristol-Myers Squibb
8.1.1. Business Overview
8.1.2. Service Portfolio
8.1.3. Strategic Developments
8.1.4. Financial Overview
8.2. Norgine Pharmaceuticals Ltd
8.2.1. Business Overview
8.2.2. Service Portfolio
8.2.3. Strategic Developments
8.2.4. Financial Overview
8.3. Eisai Company
8.3.1. Business Overview
8.3.2. Service Portfolio
8.3.3. Strategic Developments
8.3.4. Financial Overview
8.4. Vivus, Zafgen
8.4.1. Business Overview
8.4.2. Service Portfolio
8.4.3. Strategic Developments
8.4.4. Financial Overview
8.5. Takeda Pharmaceutical
8.5.1. Business Overview
8.5.2. Service Portfolio
8.5.3. Strategic Developments
8.5.4. Financial Overview
8.6. FlaxoSithKline plc
8.6.1. Business Overview
8.6.2. Service Portfolio
8.6.3. Strategic Developments
8.6.4. Financial Overview
8.7. Rhythm Pharmaceuticals
8.7.1. Business Overview
8.7.2. Service Portfolio
8.7.3. Strategic Developments
8.7.4. Financial Overview
8.8. Pfizer
8.8.1. Business Overview
8.8.2. Service Portfolio
8.8.3. Strategic Developments
8.8.4. Financial Overview
8.9. Novo Nordisk
8.9.1. Business Overview
8.9.2. Service Portfolio
8.9.3. Strategic Developments
8.9.4. Financial Overview
8.10. Shionogi USA
8.10.1. Business Overview
8.10.2. Service Portfolio
8.10.3. Strategic Developments
8.10.4. Financial Overview
9. Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.1. Global Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2027)
9.2. Anti-Obesity Therapeutics Market Forecast by Regions (2017-2027)
9.2.1. North America Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.1.1. United States Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.1.2. Canada Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.1.3. Mexico Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.2. Europe Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.2.1. Germany Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.2.2. France Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.2.3. UK Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.2.4. Russia Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.2.5. Italy Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.2.6. Rest of Europe Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.3. Asia-Pacific Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.3.1. China Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.3.2. Japan Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.3.3. Korea Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.3.4. India Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.3.5. Southeast Asia Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.3.6. Rest of Asia-Pacific Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.4. South America Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.4.1. Brazil Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.4.2. Argentina Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.4.3. Columbia Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.4.4. Rest of South America Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.5. Middle East and Africa Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.5.1. Saudi Arabia Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.5.2. United Arab Emirates Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.5.3. Egypt Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.5.4. Nigeria Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.5.5. South Africa Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.5.6. Turkey Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.2.5.7. Rest of Middle East and Africa Anti-Obesity Therapeutics Market Forecast (2017-2027)
9.3. Anti-Obesity Therapeutics Market Forecast by Product Type (2017-2027)
9.3.1. Anti-Obesity Therapeutics Forecast by Product Type (2017-2027)
9.3.2. Anti-Obesity Therapeutics Market Share Forecast by Product Type (2017-2027)
9.4. Anti-Obesity Therapeutics Market Forecast by Application (2017-2027)
9.4.1. Anti-Obesity Therapeutics Forecast by Application (2017-2027)
9.4.2. Anti-Obesity Therapeutics Market Share Forecast by Application (2017-2027)
List of Tables
List of Tables and Figures:
Figure United States Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Canada Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Mexico Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Germany Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure France Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure UK Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Russia Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Italy Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Europe Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure China Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Japan Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Korea Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure India Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Southeast Asia Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Asia-Pacific Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Brazil Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Argentina Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Columbia Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of South America Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Saudi Arabia Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure United Arab Emirates Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Egypt Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Nigeria Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure South Africa Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Turkey Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Figure Rest of Middle East and Africa Anti-Obesity Therapeutics Revenue (Million USD) and Growth Rate (2017-2025)
Table Global Anti-Obesity Therapeutics Revenue and Revenue Share by Product Type (2017-2018)
Figure Global Centrally Acting Anti-obesity Drugs Revenue and Growth Rate (2017-2018)
Figure Global Peripherally Acting Anti-obesity Drugs Revenue and Growth Rate (2017-2018)
Table Global Anti-Obesity Therapeutics Revenue and Revenue Share by Application (2017-2018)
Figure Global Hospital Use Revenue and Growth Rate (2017-2018)
Figure Global Clinic Use Revenue and Growth Rate (2017-2018)
Figure Global Other Revenue and Growth Rate (2017-2018)
Table Global Anti-Obesity Therapeutics Revenue by Regions (2017-2018)
Figure North America Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure North America Anti-Obesity Therapeutics Revenue and Growth Rate (2017-2018)
Figure North America Anti-Obesity Therapeutics by Countries (2017-2018)
Figure North America Anti-Obesity Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure United States Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure United States Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Canada Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Canada Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Mexico Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Mexico Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Europe Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Europe Anti-Obesity Therapeutics Revenue and Growth Rate (2017-2018)
Figure Europe Anti-Obesity Therapeutics by Countries (2017-2018)
Figure Europe Anti-Obesity Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Germany Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Germany Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure France Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure France Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure UK Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure UK Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Russia Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Russia Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Italy Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Italy Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Europe Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Rest of Europe Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Asia-Pacific Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Asia-Pacific Anti-Obesity Therapeutics Revenue and Growth Rate (2017-2018)
Figure Asia-Pacific Anti-Obesity Therapeutics by Countries (2017-2018)
Figure Asia-Pacific Anti-Obesity Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure China Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure China Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Japan Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Japan Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Korea Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Korea Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure India Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure India Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Southeast Asia Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Southeast Asia Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Rest of Asia-Pacific Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South America Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure South America Anti-Obesity Therapeutics Revenue and Growth Rate (2017-2018)
Figure South America Anti-Obesity Therapeutics by Countries (2017-2018)
Figure South America Anti-Obesity Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Brazil Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Brazil Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Argentina Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Argentina Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Columbia Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Columbia Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of South America Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Rest of South America Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Middle East and Africa Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Middle East and Africa Anti-Obesity Therapeutics Revenue and Growth Rate (2017-2018)
Figure Middle East and Africa Anti-Obesity Therapeutics by Countries (2017-2018)
Figure Middle East and Africa Anti-Obesity Therapeutics Revenue (Million USD) by Countries (2017-2018)
Figure Saudi Arabia Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Saudi Arabia Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure United Arab Emirates Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure United Arab Emirates Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Egypt Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Egypt Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Nigeria Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Nigeria Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure South Africa Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure South Africa Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Turkey Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Turkey Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Anti-Obesity Therapeutics Growth Rate (2017-2018)
Figure Rest of Middle East and Africa Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2017-2018)
Table Bristol-Myers Squibb Anti-Obesity Therapeutics Financial Overview
Table Norgine Pharmaceuticals Ltd Anti-Obesity Therapeutics Financial Overview
Table Eisai Company Anti-Obesity Therapeutics Financial Overview
Table Vivus, Zafgen Anti-Obesity Therapeutics Financial Overview
Table Takeda Pharmaceutical Anti-Obesity Therapeutics Financial Overview
Table FlaxoSithKline plc Anti-Obesity Therapeutics Financial Overview
Table Rhythm Pharmaceuticals Anti-Obesity Therapeutics Financial Overview
Table Pfizer Anti-Obesity Therapeutics Financial Overview
Table Novo Nordisk Anti-Obesity Therapeutics Financial Overview
Table Shionogi USA Anti-Obesity Therapeutics Financial Overview
Figure Global Anti-Obesity Therapeutics Revenue (Millions USD) and Growth Rate (2018-2025)
Table Anti-Obesity Therapeutics Market Forecast by Regions (2018-2025)
Figure North America Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure United States Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Canada Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Mexico Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Europe Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Germany Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure France Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure UK Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Russia Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Italy Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Rest of Europe Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Asia-Pacific Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure China Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Japan Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Korea Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure India Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Southeast Asia Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Rest of Asia-Pacific Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure South America Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Brazil Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Argentina Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Columbia Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Rest of South America Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Middle East and Africa Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Saudi Arabia Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure United Arab Emirates Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Egypt Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Nigeria Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure South Africa Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Turkey Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Rest of Middle East and Africa Anti-Obesity Therapeutics Market Forecast (2018-2025)
Figure Global Anti-Obesity Therapeutics Forecast by Product Type (2018-2025)
Figure Global Anti-Obesity Therapeutics Market Share Forecast by Product Type (2018-2025)
Figure Global Anti-Obesity Therapeutics Forecast by Product Type (2018-2025)
Figure Global Anti-Obesity Therapeutics Forecast by Application (2018-2025)
Figure Global Anti-Obesity Therapeutics Market Share Forecast by Application (2018-2025)
Figure Global Anti-Obesity Therapeutics Forecast by Application (2018-2025)
Please Note: Data related to the Companies are subject to Availability.
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|